trial with title COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada

Find a participating research site

If you wish to participate in this study, start typing your location below, then select it from the drop-down list. The map will be updated to show the sites located within the radius you selected, with a list of locations underneath.

Please note that the map below only shows study sites that accept online recommendations. If you cannot find a site in your area, please check again later, as study sites may be added to the study continuously.

Select Country

Site Name Address Status Distance
Centre Hospitalier Universitaire de Sherbrooke CHUS
3001 12e Avenue North
Sherbrooke, Quebec, J1H 5N4
Canada
Recruiting -- Am I Eligible?
Hopital Maisonneuve Rosemont
5415 De I'assomption Boulevard
Montreal, CA, H1T 2M4
Canada
Recruiting -- Am I Eligible?
Juravinski Cancer Centre
699 Concession Street Hematology
Hamilton, CA, L8V 5C2
Canada
Recruiting -- Am I Eligible?
Ottawa General Hospital
501 Smyth Road
Ottawa, CA, K1H 8L6
Canada
Recruiting -- Am I Eligible?
Saskatoon Cancer Center
20 Campus Dr
Saskatoon, Saskatchewan, S7N 4H4
Canada
Recruiting -- Am I Eligible?
Sir Mortimer B Davis Jewish General Hospital
3755 Cote Sainte Catherine Road
Montreal, Quebec, H3T 1E2
Canada
Recruiting -- Am I Eligible?
Sunnybrook Health Sciences Centre
2075 Bayview Avenue
Toronto, CA, M4N 3M5
Canada
Recruiting -- Am I Eligible?
Tom Baker Cancer Centre
1331 29th Street Nw
Calgary, CA, T2N 4N2
Canada
Recruiting -- Am I Eligible?
University of Alberta
4-112 Clinical Sciences Building
Edmonton, CA, T6G 2B7
Canada
Recruiting -- Am I Eligible?
Vancouver General Hospital
950 West 10th Avenue
Vancouver, British Columbia, V5Z 4E3
Canada
Recruiting -- Am I Eligible?

Learn more about study participation

Study participation lasts approximately six years (and may be shorter or longer for some patients). This includes:
• A screening period of approximately 35 days,
• an initial treatment period of 24 weeks (which can be extended if certain criteria are met and if you continue to benefit from treatment), and
• a follow-up period where you will be contacted approximately every 12 weeks to ask how you are doing.

The study drug used in the COMMANDS Trial is a protein that aims to help increase the production of red blood cells in the bone marrow. The study drug will be administered by subcutaneous injection every three weeks during the treatment period.